Scarica l'app Stockscreener
52.35
5.82%
2.88
Dopo l'orario di chiusura:
52.63
0.28
+0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$49.47
Aprire:
$47.98
Volume 24 ore:
85.80M
Relative Volume:
2.70
Capitalizzazione di mercato:
$7.41B
Reddito:
$1.24B
Utile/perdita netta:
$101.26M
Rapporto P/E:
118.98
EPS:
0.44
Flusso di cassa netto:
$149.62M
1 W Prestazione:
+58.16%
1M Prestazione:
+88.51%
6M Prestazione:
+121.63%
1 anno Prestazione:
+323.89%
Intervallo 1D:
$47.20
$52.38
Intervallo di 1 settimana:
$32.01
$52.38
Portata 52W:
$11.64
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Industria
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Confronta HIMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
52.35 | 7.41B | 1.24B | 101.26M | 149.62M | 0.44 |
|
PG
Procter Gamble Co
|
159.29 | 381.15B | 83.93B | 15.50B | 15.03B | 6.30 |
|
UL
Unilever Plc Adr
|
64.11 | 160.71B | 65.10B | 6.16B | 0 | 2.4569 |
|
CL
Colgate Palmolive Co
|
90.88 | 77.71B | 19.95B | 2.90B | 3.47B | 3.54 |
|
KVUE
Kenvue Inc
|
23.11 | 45.28B | 15.46B | 1.03B | 1.34B | 0.53 |
|
KMB
Kimberly Clark Corp
|
133.59 | 43.73B | 19.75B | 2.47B | 2.39B | 7.34 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Hims CEO Rides Weight-Loss Drug Boom to $1.1 Billion Fortune - Bloomberg.com
Hims & Hers Stock Soars 32% Since Tuesday On Strong Q1 Earnings And Robust Outlook - Benzinga
Surging Earnings Estimates Signal Upside for Hims & Hers Health (HIMS) Stock - Nasdaq
Hims & Hers: Short Squeeze Or Strong Fundamentals? (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
Hims & Hers Shows It's More Than Just GLP-1 Drugs - 24/7 Wall St.
Hims & Hers Health Inc. (HIMS) Stock: Monster Q1 Growth Can't Save Stock from After-Hours Tumble - CoinCentral
Hims & Hers Health, Inc. (NYSE:HIMS) Q1 2025 Earnings Call Transcript - MSN
Hims & Hers Health: Healthcare Disruptor Building A Durable Moat (Initiate With Buy) - Seeking Alpha
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth - Nasdaq
Why Hims & Hers Health, Inc. (HIMS) Skyrocketed On Tuesday - Yahoo Finance
Hims & Hers Stock (HIMS) Falls as Cautious Outlook Blurs Massive Revenue Growth - Yahoo Finance
This Week's Healthcare Earnings: Moderna, CVS, Hims & Hers - Law360
Hims & Hers Health, Inc. Reports Strong Q1 Earnings - TipRanks
Piper Sandler Raises Price Target for Hims & Hers Health (HIMS) to $39.00 | HIMS Stock News - GuruFocus
Hims & Hers Health (HIMS) Surges 18.12%: What’s Fueling the Rally? - Wealth Daily
Stock Movers: Palantir, Hims, Constellation Energy - Bloomberg.com
What’s driving the roller coaster ride for San Francisco’s Hims & Hers stock? - San Francisco Chronicle
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why - Yahoo Finance
Palantir, Tesla, Ford, Constellation Energy, SolarEdge, Vertex, DoorDash, and More Movers - Barron's
Wall Street Punishes HIMS--Right After It Lands a Blockbuster Weight Loss Deal - Yahoo Finance
Noteworthy Tuesday Option Activity: ROOT, HIMS, SN - Nasdaq
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped - Nasdaq
2 Reasons Hims & Hers Will Break $50sBuy Post Earnings (NYSE:HIMS) - Seeking Alpha
HIMS Q1 Earnings Call: Personalized Care and New Partnerships Drive Upside, Guidance Signals Near-Term Transition - Yahoo Finance
HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down - Yahoo Finance
Hims & Hers Health (HIMS) Price Target Raised by Citigroup | HIMS Stock News - GuruFocus
Hims surges, SolarEdge earnings beat, Rivian expands in Illinois - Yahoo Finance
Hims & Hers stock jumps after blowout quarter, long-term guidance stuns Street - Proactive financial news
Hims & Hers Stock Rises on Fundamentals and Squeeze Potential - MarketBeat
What's Going On With Hims & Hers Stock Tuesday? - Benzinga
Hims & Hers Q1 2025 slides: Sets $6.5B revenue target for 2030 amid specialty expansion - Investing.com
Hims & Hers Health Faces Strategic Choice Between Semaglutide Expansion or Core Business, BofA Says - marketscreener.com
Hims & Hers Health Weighs Expansion Vs. Core Focus - Finimize
Looking At Hims & Hers Health's Recent Unusual Options Activity - Nasdaq
Hims & Hers Stock Jumps as Q1 Sales More Than Double - Investopedia
Hims & Hers: Strong Q1 Masks Problematic Long-Term Value Proposition (NYSE:HIMS) - Seeking Alpha
Piper Sandler raises Hims & Hers stock target to $39, keeps neutral - Investing.com
Top 1% Stock, Hims & Hers Health, Dives On Lackluster Outlook - MSN
HIMS Stock Sees Profit Pressure Despite Q1 Success | HIMS Stock News - GuruFocus
Hims & Hers (HIMS) Plunges as Weak Outlook Tempers 300% Profit Jump - Yahoo
Hims & Hers (HIMS) Plunges as Weak Outlook Tempers 300% Profit J - GuruFocus
Needham maintains Buy rating on Hims & Hers with $61 price target - Investing.com India
Cowen raises Hims & Hers stock price target to $38, maintains Hold - Investing.com
BofA raises Hims & Hers stock target to $28, retains underperform - Investing.com
Hims and Hers (HIMS) PT Raised to $28 at BofA Securities - StreetInsider
What’s Next For HIMS Stock After A Solid Q1? - Forbes
What’s Next For HIMS Stock After An Upbeat Q1? - Trefis
Hims & Hers Stock Slides Pre-Market As Q2 Sales View Misses Estimates, But Retail Traders Shrug It Off - MSN
Morgan Stanley maintains Hims & Hers stock with $40 target By Investing.com - Investing.com India
BofA maintains Hims & Hers stock underperform, $26 target By Investing.com - Investing.com India
BofA maintains Hims & Hers stock underperform, $26 target - Investing.com
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.61%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):